An increase in abdominal adiposity is linked with the development of a low-grade systemic inflammatory response, characterised by altered adipokine secretion and increased plasma oxidative stress. This in turn, is thought to have a role in the increased risk of T2DM and CVD associated with obesity and interventions are therefore sought which are able to modulate plasma adipokine concentrations, re-establishing a healthy balance.

It was hypothesised that consumption of a pomegranate extract (PE) for 28 d by a healthy, overweight/obese (BMI=29.2 _sd 3.1; Age=37.1 _sd 10.2) population would alter circulating adipokines and plasma total antioxidant status. A randomised, placebo-controlled, single-blind crossover design was used, with a 14 d washout period. Measurements were taken at baseline and 28 d for each intervention, within 24 hours of the last capsule being taken. No significant changes in energy or macronutrient intake (Fig. A & B), assessed using a 3 d diet diary, BMI, waist circumference or waist:hip ratio were noted for either treatment group. Consumption of PE for 28 d did not significantly increase plasma antioxidant levels as measured by the ferric reducing antioxidant capacity (FRAP)⁽)Reference Benzie and Strain ^{1 )} or oxygen radical absorbance capacity (ORAC)⁽ Reference Girard-Lalancette, Pichette and Legault ^{2 )}, nor did it affect oxidative stress as measured by plasma thiobarbituric reactive substances assay (TBARS)⁽ Reference Buege and Aust ^{3 )}. TNFα, IL-6, adiponectin and leptin (RnD Systems, UK) did not significantly change for either treatment.

In conclusion, intake of a PE for 28 d did not result in a cumulative increase in plasma total antioxidant capacity or affect plasma oxidative stress. Nor was there any effect on plasma adipokines. These results suggest that consumption of a PE over a 28 d period has no effect on the secretory pattern of adipose tissue in obesity. However it may possibly have some action beyond this time period or at the subcellular level.